--- canonical_name: Panthenol alternate_names: Dexpanthenol, D-Panthenol, Pantothenol, D-Pantothenyl Alcohol, Provitamin B5, DL-Panthenol canonical_topic: Panthenol for Health & Longevity short_topic_lc: panthenol creation_date: 2026-0824-0302 creator_ai_fullname: Grok 4.5 --- # Panthenol for Health & Longevity
Evidence Review created on 08/24/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5 **Also known as:** Dexpanthenol, D-Panthenol, Pantothenol, D-Pantothenyl Alcohol, Provitamin B5, DL-Panthenol ## Motivation Panthenol is a stable alcohol form of vitamin B5, also sold as dexpanthenol or provitamin B5. After it is put on skin or the moist linings of the nose and eyes, the body turns it into vitamin B5. People who work on skin quality, recovery after cosmetic procedures, and comfort of dry nose or eyes meet it in creams, ointments, hair products, nasal sprays, and eye gels because it draws and holds water. Pharmacy ointments have been on European shelves since the 1940s, first for minor wounds and later as an injection meant to restart bowel movement after surgery. The bowel use receded when later controlled studies did not show a clear benefit. Skin and cosmetic use grew instead, and panthenol is now a common ingredient in creams and lotions that stay on the skin. A large share of the published skin research was funded by companies that sell dexpanthenol ointments. This review examines whether panthenol holds water in the outer skin and speeds closure of shallow wounds, what allergy and other harms are documented, and how formulation, dose, and financial conflicts of interest shape that evidence for adults already investing in long-term health. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews and primary papers that introduce panthenol's barrier, wound, and allergy evidence. - [Topical use of dexpanthenol: a 70th anniversary article](https://pubmed.ncbi.nlm.nih.gov/28503966/) - Proksch et al., 2017 Narrative review of topical dexpanthenol's moisturizing, barrier, and wound-healing evidence, including molecular work. Several authors were affiliated with Bayer Consumer Care, which markets dexpanthenol ointments. - [Topical use of dexpanthenol in skin disorders](https://pubmed.ncbi.nlm.nih.gov/12113650/) - Ebner et al., 2002 Foundational clinical review covering hydration, barrier repair, anti-inflammatory effects, and placebo-controlled wound-healing trials of topical dexpanthenol. - [Accelerated wound healing with a dexpanthenol-containing ointment after fractional ablative CO₂ laser resurfacing of photo-damaged skin in a randomized prospective clinical trial](https://pubmed.ncbi.nlm.nih.gov/30897983/) - Heise et al., 2019 Randomized split-site trial after fractional carbon-dioxide laser: dexpanthenol ointment closed laser lesions faster than petroleum jelly in the first five days. - [Skin moisturizing effects of panthenol-based formulations](https://pubmed.ncbi.nlm.nih.gov/21982351/) - Camargo et al., 2011 Controlled forearm study comparing 0.5%, 1.0%, and 5.0% panthenol: the 1.0% and 5.0% formulas reduced water loss through intact skin after 30 days. - [Panthenol Allergic Contact Dermatitis: Sources of Exposure, Reported Cases, and a Call for More Frequent Testing](https://pubmed.ncbi.nlm.nih.gov/39714944/) - Weber & Hylwa, 2025 Reviews panthenol contact allergy, product sources, and rising patch-test positivity, and argues for more frequent testing of this common cosmetic ingredient. Rhonda Patrick mentioned panthenol only as one ingredient in a personal skincare list in FoundMyFitness Q&A #32 (5 Feb 2022), which did not meet the depth bar for listing. No panthenol commentary was found from Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io. Life Extension Magazine mentioned panthenol only briefly inside a multi-ingredient eyelash article, which did not meet the depth bar for listing. ## Grokipedia - [Panthenol](https://grokipedia.com/page/Panthenol) Overview of panthenol chemistry, conversion to vitamin B5, cosmetic and wound uses, and the uncommon contact-allergy signal. ## Examine No Examine.com article for panthenol was found. ## ConsumerLab No ConsumerLab article for panthenol was found. ## Systematic Reviews PubMed systematic reviews and meta-analyses that include panthenol or dexpanthenol among topical skin interventions. - [Preventive and curative approaches to diaper dermatitis in children: a systematic review](https://pubmed.ncbi.nlm.nih.gov/41014074/) - Octarica et al., 2025 Thirteen-study pediatric review; barrier creams containing zinc oxide or dexpanthenol were among the more effective, well-tolerated options. - [Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review](https://pubmed.ncbi.nlm.nih.gov/27957620/) - Ferreira et al., 2017 Thirteen randomized trials of topical prevention, including dexpanthenol; no regimen showed a consistent advantage. - [Prevention of and therapies for nipple pain: a systematic review](https://pubmed.ncbi.nlm.nih.gov/16020410/) - Morland-Schultz & Hill, 2005 Breastfeeding nipple-pain review including dexpanthenol; no topical agent was clearly superior to latch education. No systematic review of panthenol contact allergy, the principal documented harm, was found. ## Mechanism of Action Panthenol is the alcohol analog of pantothenic acid (vitamin B5). Only the D-form (dexpanthenol) is converted to vitamin B5 and then into coenzyme A (CoA, a helper molecule that carries acyl groups in fat and energy chemistry). The L-form still binds water, so moisturization does not require the D-form. Topical panthenol penetrates outer skin and moist linings more readily than pantothenic acid. There it acts as a humectant (a water-binding agent) and as a pantothenate source for fatty-acid and sphingolipid synthesis that rebuilds barrier lipid lamellae. Three accounts of action sit side by side. One is physicochemical: hygroscopic (water-attracting) water binding that lowers water loss through intact skin. Another is biochemical: CoA-dependent lipid synthesis and fibroblast proliferation. A third, from gene-array work in injured human skin ([Heise et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22759998/)), reports upregulation of IL-6 (interleukin-6, an early wound-signaling protein), IL-1β (interleukin-1 beta), CYP1B1 (a cytochrome P450 xenobiotic-metabolizing enzyme), and CXCL1 (a neutrophil-recruiting chemokine), with downregulation of psoriasin (S100A7, an antimicrobial skin protein). These accounts are not mutually exclusive; their relative weight is not settled. A plasma half-life after ordinary topical use is not well characterized. Converted pantothenic acid is water-soluble and excreted in urine; absorbed topical amounts are typically below dietary intake. After injection, dexpanthenol is rapidly oxidized to pantothenic acid. CoA selectivity is limited to the D-form. Topical distribution is mainly the outer and just-under skin layers, with uptake on moist linings. Primary metabolism is oxidation to pantothenic acid, then CoA assembly, not cytochrome P450 clearance of panthenol itself. ## Historical Context & Evolution Roche introduced a topical dexpanthenol ointment (Bepanthen) in the 1940s for minor wounds, burns, and irritated skin. The same chemistry later appeared as injectable dexpanthenol (Ilopan in the United States), given into muscle or slowly into a vein at 250–500 mg to stimulate gut movement after surgery, on the theory that CoA supports acetylcholine synthesis. A later controlled series did not show a reliable benefit for postoperative ileus (failure of bowel movement after surgery) ([Watne et al., 1962](https://pubmed.ncbi.nlm.nih.gov/14005261/)), and that use receded even though product labels in some markets still describe it. Dermatology and cosmetics kept the topical franchise. Placebo-controlled work in the 2000s measured hydration and barrier repair after detergent challenge. From the 2010s, laser and other procedure aftercare became a research focus, much of it funded by Bayer Consumer Care after it acquired the Bepanthen line. The [Cosmetic Ingredient Review Expert Panel](https://www.cir-safety.org/supplementaldoc/safety-assessment-panthenol-pantothenic-acid-and-derivatives-used-cosmetics-0) (CIR; an industry-funded cosmetics safety panel) concluded in 1987 and again in 2018 that panthenol is safe in present cosmetic use concentrations, while noting uncommon sensitization. Patch-test clinics have since reported a higher rate of positive reactions as testing has become more frequent. Current opinion is therefore split by use case: topical barrier and minor-wound care remain active; injectable bowel stimulation does not rest on later controlled evidence. ## Expected Benefits ### High 🟩 🟩 🟩 #### Outer-skin hydration and reduced water loss Topical panthenol at 1–5% raises water content of the outer skin and lowers transepidermal water loss (TEWL, evaporation through intact skin) versus vehicle in more than one randomized human study. Proposed mechanisms include humectant water binding and support of lipid synthesis after conversion to pantothenic acid. Independent and manufacturer-funded trials both show this biophysical signal; several positive studies were funded by Bayer Consumer Care, which sells dexpanthenol ointments. The measured endpoint is a standard barrier surrogate, not a hard disease event. **Magnitude:** After 30 days, 1.0% and 5.0% panthenol reduced TEWL versus vehicle ([Camargo et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21982351/)); a 3-week panthenol emollient produced a larger TEWL area-under-the-curve reduction than untreated skin (−168 vs −123 g/m²/h) ([Stettler et al., 2017](https://pubmed.ncbi.nlm.nih.gov/27425824/)). #### Superficial wound re-epithelialization (skin-surface regrowth) After fractional ablative carbon-dioxide laser and similar clean, shallow injury, dexpanthenol ointment has closed laser lesions faster than petroleum jelly in randomized split-site work, with better early re-epithelialization and cosmetic scores in the first five days. Gene-expression studies in injured human skin report upregulation of wound-associated transcripts. Many post-procedure papers were authored or funded by Bayer. The signal is for minor, clean, superficial wounds, not chronic ulcers. **Magnitude:** In 38 adults after fractional carbon-dioxide laser, lesion diameter favored dexpanthenol ointment over petroleum jelly on days 1 and 2, and re-epithelialization on days 1, 2, and 5; all sites were healed by day 14 ([Heise et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30897983/)). The literature reports no between-arm lesion-diameter outcome figure. ### Medium 🟩 🟩 #### Eczema symptom control in dry, inflamed skin Panthenol-containing emollients have reduced local SCORAD (SCORing Atopic Dermatitis, a named eczema severity scale) during maintenance of childhood atopic dermatitis, and a petrolatum–panthenol ointment improved chronic hand-eczema scores in line with a mild steroid–urea cream in one split-hand trial. These are clinical symptom endpoints, but several products mix panthenol with petrolatum or other lipids, so panthenol is not fully isolated. A 2022 narrative review favoring dexpanthenol in atopic dermatitis included Bayer Korea authors ([Cho et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35887707/)). **Magnitude:** In 26 adults with mild-to-moderate chronic hand eczema, petrolatum–panthenol ointment improved HECSI (Hand Eczema Severity Index) at day 28 and reduced TEWL more than 0.1% triamcinolone in 10% urea cream ([Lueangarun et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40078865/)). The literature reports no outcome figure. ### Low 🟩 #### Radiation-associated skin injury ⚠️ Conflicted Dexpanthenol creams are widely used during radiotherapy, but a systematic review of topical prevention in head-and-neck radiotherapy found no consistent advantage. A later randomized comparison in breast radiotherapy reported lower dermatitis grades with ectoin than with dexpanthenol. Net reading: no consistent advantage over other topicals for radiation-associated skin injury. **Magnitude:** No consistent grade reduction versus other topicals in pooled head-and-neck trials ([Ferreira et al., 2017](https://pubmed.ncbi.nlm.nih.gov/27957620/)); ectoin 7% had a lower dermatitis grade than dexpanthenol 5% at week 2 in 50 people receiving breast radiotherapy ([Abd Elazim et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37792331/)). The literature reports no outcome figure. #### Hair density with injectable biotin plus dexpanthenol Weekly intramuscular (into muscle) biotin plus dexpanthenol for six weeks reduced combing-test hair fall and raised total hair density in one randomized brand-comparison study of diffuse hair loss. Panthenol was never given alone, so dexpanthenol's share versus biotin cannot be separated. **Magnitude:** Hair-fall count and total density improved versus baseline at one and eight weeks after six weekly injections; terminal-to-vellus ratio differed by brand ([Samadi et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35791704/)). The literature reports no outcome figure. #### Nasal dryness Nasal dexpanthenol sprays and ointments are used for dry-nose symptoms. A three-arm randomized trial found hyaluronic acid plus dexpanthenol improved rhinitis-sicca scores (a named dry-nose symptom scale) similarly to hyaluronic acid or saline, with higher perceived moisturization in the dexpanthenol arm. Panthenol was not tested alone. **Magnitude:** In 240 people with dry-nose symptoms, rhinitis-sicca scores fell over 4 weeks by 8.42 (hyaluronic acid plus dexpanthenol), 8.90 (hyaluronic acid), and 8.94 (saline); moisturization perception was higher with the dexpanthenol arm ([Thieme et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32067777/)). #### Dry-eye surface comfort Dexpanthenol eye drops are used for dry-eye and after minor corneal injury. A randomized trial of dexpanthenol-containing tears improved corneal epithelial permeability versus identical drops without dexpanthenol. A separate foreign-body trial found a calf-blood gel closed epithelium faster than vitamin A plus dexpanthenol. **Magnitude:** In 50 people with dry eyes, dexpanthenol tears improved corneal epithelial permeability versus dexpanthenol-free drops after 6 weeks ([Göbbels & Gross, 1996](https://pubmed.ncbi.nlm.nih.gov/8992089/)). The literature reports no outcome figure. ### Speculative 🟨 #### Systemic healthspan via coenzyme A Oral or injected panthenol can raise pantothenate available for CoA, but human aging or mitochondrial outcomes from panthenol itself are lacking. The basis is mechanistic only. ## Benefit-Modifying Factors - **Genetic polymorphisms:** No established variant is known to change topical panthenol response. Butyrylcholinesterase (BCHE, the plasma enzyme that clears succinylcholine) matters only if injectable dexpanthenol is combined with that anesthetic. - **Baseline barrier status:** Drier, higher-TEWL skin shows larger hydration gains in forearm studies; already well-hydrated skin has less room to move on corneometry (instrumental skin-hydration reading). - **Sex:** Efficacy trials are not clearly sex-split. Contact-allergy case series include more women, likely reflecting higher leave-on cosmetic exposure rather than a proven pharmacologic sex difference. - **Pre-existing skin disease:** People with atopic dermatitis or chronic hand eczema have more barrier deficit to recover; infected, heavily exudative (weeping fluid), or ischemic (poor-blood-flow) ulcers are a different wound biology than the laser and abrasion models. - **Age:** Panthenol emollients have been tolerated in infants in manufacturer studies. Older adults have higher baseline TEWL and dry-skin burden, which is the setting where barrier endpoints matter most. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: documented adverse events come from patch-test cohorts and case series rather than replicated controlled trials of safety endpoints. ### Medium 🟥 🟥 #### Allergic contact dermatitis Delayed panthenol allergy presents as eczema at sites of leave-on creams, hair products, wipes, or wound ointments, including products marketed as gentle. A 2025 review of reported cases found patch-test positivity rising from about 0.2–0.7% historically to 1.2% in more recent clinic series as testing increased. The reaction is uncommon relative to how widely panthenol is used, but it is a true immune response, not mere dryness, and it recurs with re-exposure. **Magnitude:** Recent patch-test series report about 1.2% positive reactions, up from 0.2–0.7% in older clinic data ([Weber & Hylwa, 2025](https://pubmed.ncbi.nlm.nih.gov/39714944/)). ### Low 🟥 #### Contact urticaria from hair products Immediate urticaria (hives), itch, and facial swelling have been documented after panthenol-containing hair conditioner. Evidence is limited to case reports, not controlled incidence studies. **Magnitude:** Not quantified in available studies. Only isolated case reports exist, including a documented hair-conditioner reaction ([Schalock et al., 2000](https://pubmed.ncbi.nlm.nih.gov/11011922/)). #### Prolonged neuromuscular blockade after injection ⚠️ Conflicted Injectable dexpanthenol is labeled to prolong succinylcholine (a depolarizing muscle relaxant used for intubation). A 1969 reappraisal trial did not confirm that effect ([Smith et al., 1969](https://pubmed.ncbi.nlm.nih.gov/5813067/)); manufacturers still warn. Topical cream is not this setting. Net reading: product labels retain the anesthesia-window caution despite the negative trial. **Magnitude:** Not quantified in available studies. Product information lists the interaction; the 1969 reappraisal did not confirm prolongation ([Smith et al., 1969](https://pubmed.ncbi.nlm.nih.gov/5813067/)). #### Parenteral gastrointestinal, blood-pressure, and breathing effects Injectable dexpanthenol labels list cramping or diarrhea, caution in hemophilia (an inherited bleeding disorder), slight blood-pressure drops if given undiluted into a vein, and breathing difficulty. These are labeled injectable effects, not cream use. The basis is product information and older ileus literature, not modern incidence trials. **Magnitude:** Not quantified in available studies. Product information lists the effects; a 1962 postoperative-ileus paper is the older gut-motility literature ([Watne et al., 1962](https://pubmed.ncbi.nlm.nih.gov/14005261/)). ### Speculative 🟨 #### Systemic toxicity from topical use Animal studies and the CIR assessment describe low systemic toxicity, with absorbed topical amounts below dietary pantothenate intake. No human organ-toxicity signal is established; the basis is exposure math, not clinical disease outcomes. ## Risk-Modifying Factors - **Genetic polymorphisms:** No topical-panthenol metabolizer genotype is in clinical use. Inherited BCHE deficiency would theoretically magnify injectable dexpanthenol's interaction with succinylcholine, not cream use. - **Baseline biomarkers:** Blood pantothenate is not a useful risk marker for topical use. A prior positive panthenol patch test is the measurable baseline that raises later contact-allergy risk. - **Baseline skin reactivity:** A history of cosmetic or wound-ointment eczema raises the chance that a new panthenol leave-on product is the allergen; patch testing identifies it. - **Sex:** Published contact-allergy series include more women, consistent with higher exposure to leave-on hair and face products. - **Pre-existing disease:** Broken, eczematous, or freshly lasered skin increases both benefit and allergen contact. Mechanical bowel obstruction is a labeled reason to avoid injectable dexpanthenol. - **Age:** Infant data show good topical tolerability in manufacturer emollient studies. Older adults use more leave-on products and have thinner barriers, so both hydration benefit and contact-allergy opportunity rise. ## Key Interactions & Contraindications - **Succinylcholine (suxamethonium):** Caution with injectable dexpanthenol; may prolong neuromuscular blockade. Separate from anesthesia or avoid injectable panthenol in that window. Topical cream is not this setting. - **Other cholinergic gut stimulants (neostigmine, metoclopramide):** Caution if injectable dexpanthenol is used; additive gut motility and cholinergic tone. Monitor cramping and diarrhea. - **Topical corticosteroids (hydrocortisone, triamcinolone):** Monitor. Additive barrier care; some protocols use panthenol emollients to spare steroid days. Not a pharmacokinetic clash; watch for steroid under-treatment of flares. - **Other humectants (glycerin, hyaluronic acid, urea):** Caution. Additive water-binding on skin or mucosa; usually well tolerated. Stinging can increase on broken skin. - **Pantothenic acid / calcium pantothenate / pantethine:** No interaction of concern. Same vitamin-B5 family; oral forms add systemic pantothenate and are not interchangeable with topical panthenol. **Populations who should avoid Panthenol:** - Documented delayed or immediate allergy to panthenol, dexpanthenol, or pantothenic acid (absolute contraindication for that route) - Injectable dexpanthenol in mechanical intestinal obstruction - Injectable dexpanthenol in the immediate succinylcholine anesthesia window - None identified for ordinary topical use in people without panthenol allergy ## Risk Mitigation Strategies - **Patch-test before daily face or hair products:** Unexplained facial, scalp, or wound-site eczema is a setting where panthenol patch testing before a new daily product reduces repeat allergic contact dermatitis. - **D-form at 1–5%:** Studied cosmetic and ointment strengths cluster at 1–5%, which keeps allergen dose in the range of the barrier trials and reduces repeat contact-allergy exposure from untested high-percent serums. - **Stop and substitute on new eczema:** New local eczema after a cream, wipe, or hair product is a signal to stop that product and switch to a panthenol-free ointment, ending ongoing allergen exposure. - **Keep injections out of anesthesia day:** Injectable dexpanthenol is kept out of the succinylcholine anesthesia window, which mitigates prolonged paralysis. - **No undiluted intravenous injection:** Injectable dexpanthenol is not pushed undiluted into a vein, which is the labeled setting for blood-pressure drops and breathing difficulty. - **Clean, shallow wounds only:** Literature use is on minor abrasions and post-procedure skin, not as sole care for infected or ischemic ulcers, which would increase allergen contact on broken skin. ## Therapeutic Protocol - **European ointment standard:** 5% dexpanthenol ointment (Bepanthen line, Roche then Bayer) applied thinly one to three times daily to irritated or recently injured skin is the most studied topical pattern. - **Barrier-maintenance cream:** 1–5% panthenol in a leave-on emollient once or twice daily, as in the Camargo and Stettler forearm protocols, is the hydration pattern. - **Post-procedure aftercare:** Immediate occlusive dexpanthenol ointment after fractional laser, as used by Baron and colleagues at RWTH Aachen, versus bland petroleum jelly. - **Hair-clinic injections:** Some clinics give weekly intramuscular biotin 5 mg plus dexpanthenol 250 mg for six weeks for diffuse shedding; this is a combination protocol, not panthenol alone. - **Time of day:** Not time-critical. Application after bathing, while skin is slightly damp, matches ordinary emollient practice. - **Half-life and splitting:** Topical plasma half-life is not well defined; twice-daily splitting matches the randomized cream studies. Injectable dexpanthenol is rapidly oxidized to pantothenic acid. - **Genetics:** No dose-guiding polymorphism for topical use. BCHE status is relevant only around injectable use and succinylcholine. - **Sex:** No established dose split by sex. Women with prior cosmetic eczema warrant a higher index of suspicion for contact allergy. - **Age:** Older dry skin is a typical twice-daily emollient setting. Infant-specific medical use is outside this audience. - **Baseline hydration:** Lower corneometry or higher TEWL is the usual reason to choose a panthenol emollient over a fragrance-heavy cosmetic. - **Skin disease:** Mild atopic or hand eczema can use panthenol emollients as steroid-sparing maintenance, not as sole therapy for infected or exudative disease. ## Discontinuation & Cycling - **Duration of use:** Topical panthenol is an as-needed or daily barrier product, not a lifelong systemic medication. Use can continue while dry-skin or post-procedure indications persist. - **Withdrawal:** No withdrawal syndrome is described after stopping topical or oral panthenol. Dryness may return to baseline as the humectant is removed. - **Taper:** No taper is required for topical or ordinary oral use. Injectable bowel-stimulation courses were short and are not a current healthspan protocol. - **Cycling:** No tachyphylaxis (loss of effect from continuous use) is documented for barrier or wound endpoints, so cycling is not used to preserve efficacy. - **Allergy stop rule:** New localized eczema after a panthenol product is a reason to stop that product rather than cycle it. ## Sourcing and Quality - **Enantiomer:** D-Panthenol (dexpanthenol) feeds CoA synthesis; DL-Panthenol still moisturizes. Labels that specify D-Panthenol match the clinically studied biologic form. - **Strength:** Leave-on skin studies cluster at 1–5%; 5% ointment is the common pharmacy wound strength. Higher untested percentages add little documented benefit. - **Third-party testing:** For oral panthenol or B5 products, United States Pharmacopeia assay and contaminant testing matter. For topicals, a named concentration and a simple vehicle matter more than a supplement seal. - **Reference product:** Bepanthen 5% dexpanthenol ointment is the formulation behind much of the European clinical literature; generic 5% dexpanthenol ointments are widely sold. - **CIR bound:** The industry-funded CIR panel judged panthenol safe at present cosmetic concentrations and cautioned against use in products where N-nitroso compounds can form. ## Practical Considerations - **Time to effect:** Hydration and TEWL shifts appear within hours to a few days of twice-daily use; post-laser lesion-size differences were visible by days 1–2; full re-epithelialization in those trials was complete by two weeks. - **Common pitfalls:** Confusing panthenol with oral calcium pantothenate or with pantethine (a different B5-related lipid-lowering compound). Expecting radiation-dermatitis or hair-growth results equal to barrier effects. - **Regulatory status:** In the United States, panthenol is used in cosmetics and some over-the-counter skin products; the U.S. Food and Drug Administration lists it as GRAS (generally recognized as safe) as a food ingredient. Injectable bowel-stimulation products are a separate, older drug use. - **Cost and access:** Topical panthenol is inexpensive and sold in pharmacies and cosmetic lines worldwide. Cost is not a limiting factor for this intervention. ## Interaction with Foundational Habits - **Sleep:** Direct. Reduced itch and tightness from a repaired barrier can ease nocturnal scratching; panthenol is not a hypnotic. Evening ointment is the usual pattern when dry-skin itch disturbs sleep. - **Nutrition:** Indirect. Topical panthenol is not a replacement for dietary vitamin B5 from meat, eggs, and legumes. No depletion of other nutrients is described. Ordinary diet covers B5 for most adults. - **Exercise:** Direct on friction sites. Sweat and chafing raise TEWL; a 1–5% panthenol emollient on prone skin is the same barrier use as in detergent-challenge studies, applied after cooling down. - **Stress management:** None established. No human cortisol or autonomic data for panthenol. Stress-related itch still tracks barrier care, not a panthenol-specific stress pathway. ## Monitoring Protocol & Defining Success Baseline, before a new daily leave-on panthenol product, is a look at the intended skin: dryness, fissures, post-procedure wounds, and any prior product-site eczema. Unexplained facial or scalp dermatitis can be followed by a panthenol patch test before a hair or face product. Blood pantothenate is not a useful start-up test for topical use. After laser or abrasion care, photograph the field on day 0. Ongoing checks sit at days 2–7 for wound or post-procedure use, at 2–4 weeks for barrier creams, then only if the skin changes. Repeat TEWL or corneometry, if used, at the same site and time of day. New itch or eczema at the application site is a stop signal for allergy. Success is less tightness and flaking, faster closure of shallow wounds versus the person's usual bland ointment, and no new contact dermatitis. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | Skin hydration (corneometry) | Rise from the person's own baseline; no universal functional target | Confirms the humectant effect | Not a blood test; same site and time of day | | TEWL | Directional drop from the irritated or dry baseline; no universal functional target | Tracks barrier repair | Varies by site and climate; facial values run higher than forearm | | Panthenol patch test | Negative | Finds delayed allergy before daily face or hair use | Use if prior product-site eczema; read at 48–96 hours | | Visual irritation / itch | None to minimal | Catches early contact dermatitis | Daily in the first two weeks of a new leave-on product | Qualitative markers: - Tightness, flaking, and sting after washing - Speed of scab or laser-dot closure versus the person's usual ointment - New itch or eczema exactly where the product sits - Nasal or eye comfort if a mucosal formula is used ## Emerging Research - **Hydrogel plaster trial:** [NCT07642973](https://clinicaltrials.gov/study/NCT07642973) is a planned randomized abrasion-model study of a dexpanthenol hydrogel patch versus a standard plaster and dry healing (n=40), with re-epithelialization as the primary endpoint. - **Injected chronic wounds:** [NCT07395674](https://clinicaltrials.gov/study/NCT07395674) will test perilesional (around the wound) subcutaneous dexpanthenol plus standard care versus standard care alone in diabetic, venous, and arterial ulcers (n=40), a setting topical trials have not established. - **Post-PRK (photorefractive keratectomy) eye drops:** [NCT06822608](https://clinicaltrials.gov/study/NCT06822608) will compare dexpanthenol–hyaluronic acid drops for corneal epithelialization after that surgery (n=68), where older foreign-body data favored a calf-blood gel over vitamin A plus dexpanthenol ([Egger et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10420108/)). - **Rising contact allergy:** Independent patch-test reviews report higher panthenol positivity as testing spreads ([Weber & Hylwa, 2025](https://pubmed.ncbi.nlm.nih.gov/39714944/)), a signal that could weaken the “hypoallergenic moisturizer” framing. - **Manufacturer-heavy literature:** Much barrier and laser aftercare evidence remains Bayer-funded. Independent replications of the [Heise et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30897983/) laser and [Stettler et al., 2017](https://pubmed.ncbi.nlm.nih.gov/27425824/) emollient findings would either firm or shrink the effect sizes now cited. ## Conclusion Panthenol is a vitamin B5 precursor used on skin and moist linings. For adults already investing in skin quality, the strongest human signal is that 1–5% formulas left on the skin hold water in the outer skin and speed closure of clean, shallow wounds after cosmetic laser treatment. That signal comes from more than one randomized study. A large share of the positive dermatology literature was paid for by Bayer Consumer Care, which sells dexpanthenol ointments, so the size of the effect in independent practice is less certain than the direction. The industry-funded Cosmetic Ingredient Review Expert Panel judged topical strengths safe while noting allergy. Inflamed dry skin such as eczema can improve with panthenol-containing moisturizing creams, though many of those products mix panthenol with petroleum jelly or other lipids. Hair and radiation-skin claims rest on weaker or mixed human data. Injections meant to restart the bowel after surgery did not hold up in later controlled work. The main documented harm is delayed contact allergy, uncommon but reported more often as testing has increased. Immediate itchy swellings from hair products are rare. Injections can prolong a muscle relaxant used in anesthesia. Ordinary topical use does not require blood tests; watching the skin for new itch or rash is the practical safety check. Panthenol is inexpensive, widely available as D-Panthenol, and is not a substitute for dietary vitamin B5. It is a barrier and wound-care ingredient with a favorable local safety record in people who are not allergic to it. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**